# Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

> **NCT00469898** · PHASE2 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 50 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00469898
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2008-07
- **Final completion:** 2010-07
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2012-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00469898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00469898, "Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00469898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*